Firms spend £4.4bn as skills shortage bites

first_imgThen employers spent a total of £6.3bn. They have cut back the most on increasing salaries to attract better staff. Share Most employers in the UK have struggled to find skilled staff in the last year, a new study reveals today. whatsapp The shortage has forced British firms to spend £4.4bn on temps, higher salaries, recruitment fees and training. “Training, such as apprenticeships, provides a long-term solution to UK organisations looking to adapt to challenges on the horizon such as Brexit, digitisation and new technologies,” said Willett. Around half of the businesses surveyed hired temporary staff, while 44 per cent spent more than they intended on recruiters. Around a third hired staff at a lower level than they needed, while 38 per cent increased salaries. August Graham However, the amount spent on closing the skills shortage actually fell from last year, the figures show. center_img whatsapp The development means that 61 per cent of businesses are now trying to develop internal talent. “It’s encouraging that employers are looking to invest in the talent of their existing workforce, with businesses increasingly turning to strategies that will serve their skills requirements for the years to come,” said David Willett, corporate director at the Open University. Monday 8 July 2019 12:01 am And three in five senior business leaders worry that the shortage will get worse after Britain leaves the EU. Britain’s skills shortage comes as employment is at its highest point since 1971. Businesses are therefore having to search for staff from a smaller pool. Firms spend £4.4bn as skills shortage bites Data from the Open University shows that 68 per cent of employers have struggled to find the right kind of staff in the past 12 months. last_img read more

City jobs at risk as Deutsche Bank slashes 18,000 roles globally

first_imgThe radical overhaul follows a series of reforms by Deutsche aimed at halting its decline and tumbling share price. Germany’s biggest lender will shut down its global share-trading business and significantly cut back its investment banking operations in a drastic overhaul. Deutsche says the restructuring will cost it €7.4bn (£6.6bn). Thousands of jobs are at risk in the City of London after Deutsche Bank announced it will slash 18,000 roles globally in an attempt to stem its 10-year decline. Deutsche will also cut back its fixed income operations, which deal in instruments such as government and corporate bonds. whatsapp Sunday 7 July 2019 6:56 pm Deutsche cancelled its dividend for both this year and next. It also said it will not issue shares to pay for the turnaround plans. Over the last five years shares have fallen over 70 per cent. Worth almost €90 before the financial crisis, they are valued at around €7 today. The bank did not reveal exactly where the job losses would be felt but around 7,000 people work for Deutsche in London, which is home to the bank’s largest investment finance operations, making major cutbacks likely. Sewing called the plans a “restart” but they will be interpreted as an admission by Deutsche that it cannot compete with the giant US investment banks on Wall Street. “But the structural challenges haven’t blown over, its main rivals haven’t dropped out and Deutsche’s cost base, culture, structure and share price have finally caught up with it.” Fresh start William Wright, founder of the capital markets think tank New Financial said: “The restructuring at Deutsche Bank is the result of 10 years of tinkering at the edges of a business that had grown too big and too quickly in the decade before the financial crisis. Share City jobs at risk as Deutsche Bank slashes 18,000 roles globally The announcement came after the bank’s board met on Sunday to give the overhaul the green light. Sewing promised big changes in the wake of the failed merger with Commerzbank two months ago. Deutsche will also create a corporate bank which will focus on transaction finance. Deutsche said it will feel the cost immediately, predicting a loss of €2.8bn in the second quarter of 2019 as it shells out for severance payments and restructuring costs. Pedestrians walk past an office of Deutsche Bank in London on August 28, 2014. The German lender Deutsche Bank has been fined more than 4.7 million GBP (7.8 million USD, 5.9 million euros) for incorrectly reporting some financial transactions, regulators said on August 28. AFP PHOTO / JUSTIN TALLIS (Photo credit should read JUSTIN TALLIS/AFP/Getty Images) As part of the plans Germany’s flagship lender will also create a “bad bank” to hive off €74bn of unwanted assets such as long-dated derivatives. Sewing will take responsibility for both the new corporate bank as well as the investment bank. Garth Ritchie, who previously headed the investment unit, left the bank on Friday. “Deutsche Bank was a disciple of the ‘promised land’ theory of investment banking: if we can just keep going for a few more years, we’ll be able to print money on the other side when others drop out and this all blows over,” added Wright. More From Our Partners ‘Neighbor from hell’ faces new charges after scaring off home buyersnypost.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.org Harry Robertson Read more: Deutsche Bank investment chief quits ahead of shakeup whatsapp Chief executive Christian Sewing said Deutsche was “refocusing the bank around our clients”.  by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May Likebonvoyaged.comThese Celebs Are Complete Jerks In Real Life.bonvoyaged.comPast Factory4 Sisters Take The Same Picture For 40 Years. Don’t Cry When You See The Last One!Past FactoryZen HeraldEllen Got A Little Too Personal With Blake Shelton, So He Said ThisZen HeraldFilm OracleThey Drained Niagara Falls – Their Gruesome Find Will Keep You Up All NightFilm OracleDefinitionMost Embarrassing Mistakes Ever Made In HistoryDefinitionPsoriatic Arthritis | Search AdsWhat Is Psoriatic Arthritis? See Signs (Some Symptoms May Surprise)Psoriatic Arthritis | Search AdsUnderstand Solar$0 Down Solar in Scottsdale. How Much Can You Save? Try Our Free Solar Calculator Now.Understand SolarMisterStoryWoman files for divorce after seeing this photoMisterStoryDaily Funny40 Brilliant Life Hacks Nobody Told You AboutDaily Funny Read more: Deutsche Bank poised to announce huge job losses on Monday The exact locations of the job cuts are not expected to be known for some time. Deutsche said it aims to reduce its number of employees to 74,000 by 2022. Sylvia Matherat, chief regulatory officer since 2015, and Frank Strauss, management board members since 2017, will follow Ritchie in leaving the bank. “We are returning to our roots and to what once made us one of the leading banks in the world,” he said.last_img read more

Panel at Bethel convention seeks solution to tribal child welfare problems

first_imgAlaska Native Government & Policy | Family | Government | Southwest | State GovernmentPanel at Bethel convention seeks solution to tribal child welfare problemsSeptember 30, 2015 by Anna Rose MacArthur, KYUK Share:Valerie Davidson, commissioner of the state’s Dept. of Health and Social Services, led the panel on tribal-state child welfare in the AVCP region. (Photo by Anna Rose MacArthur/KYUK)Keeping tribal children in their tribal communities is the solution to improving regional child welfare, panelists said Monday at the Association of Village Council Presidents annual conventionThe panelists represented a range of local, regional and state organizations and said the approach to keeping children in their tribal communities is two-pronged.The first is by training more foster parents in each village. There is especially a need for therapeutic foster parents. Such parents receive extra training and an additional stipend to provide behavioral health services to foster children.Panelist Fennisha Gardner, Southwest regional director of children services, said currently there are no therapeutic foster parents in the Bethel area. Without these parents, many children are removed from their homes because they require therapeutic services not available in their communities.Panelist Linda Ayagarak-Daney, an AVCP social worker, said many foster parents are acting in a therapeutic way by engaging their foster children in cultural practices like berry picking, subsisting and boating.Monique Vondall-Rieke. (Photo courtesy of South Dakota State University)Another solution panelists offered was to continue establishing and empowering tribal courts. Many panelists said tribes, not the state, know best how to care for their children.The AVCP recently hired Monique Vondall-Rieke to help establish tribal courts throughout the region. Her vision is to create 25 to 30 new courts. To do that, she will soon begin tribal court assessments in AVCP villages.Vondall came from working with the Chippewa Tribe in North Dakota as a tribal judge and attorney. She was also responsible for writing tribal court code.The convention goes until Thursday at the Bethel Cultural Center.Share this story:last_img read more

Defence secretary in climb down following anti-migration gaffe

first_img More From Our Partners Native American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comSupermodel Anne Vyalitsyna claims income drop, pushes for child supportnypost.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgUK teen died on school trip after teachers allegedly refused her pleasnypost.com Share Kate McCannKate McCann is a reporter at City A.M. She covers politics and insurance and can be contacted at [email protected] DEFENCE secretary Michael Fallon has been forced to admit he should have chosen his words more carefully, after claiming that British towns are “swamped” with immigrants during a television interview. Speaking on Sky’s Murnaghan programme yesterday, Fallon said: “In some areas, particularly on the east coast, yes, towns do feel under siege from large numbers of migrant workers and people claiming benefits and it’s quite right that we look at that.” He also refered to towns being “swamped by huge numbers of migrant workers”.Last night, a Downing Street source said Fallon “accepts he should have chosen his words better”, adding that the defence secretary ought to have used the phrase “under pressure” instead. Fallon was discussing David Cameron’s plan to renegotiate the UK’s relationship with Europe, which has centred on the free movement of people. Yesterday, German chancellor Angela Merkel said her country would not back the Prime Minister’s bid to limit the number of migrant workers entering Britain from the rest of the EU. It comes as Cameron faces mounting pressure from MPs of all parties to reject a demand from Brussels for a £1.7bn top-up payment by 1 December. On Friday the Prime Minister said the EU “had another thing coming” if leaders expect the UK to pay up on time. Show Comments ▼ whatsapp whatsapp Defence secretary in climb down following anti-migration gaffe Monday 27 October 2014 12:10 am Tags: NULLlast_img read more

We’ve known for 50 years what causes sickle cell disease. Where’s the cure?

first_img Privacy Policy Newsletters Sign up for Weekend Reads Our top picks for great reads, delivered to your inbox each weekend. Watch: Episode 3: Scientists are building mini-brains to understand the human mind Leave this field empty if you’re human: Camille began taking the only Food and Drug Administration-approved sickle cell drug, hydroxyurea, after the pain crisis. Hydroxyurea is an old cancer medication whose effect on sickle cell was discovered serendipitously by Nathan and his colleagues at Boston Children’s. It can reduce episodes of sickle cell crisis, but helps only about half of patients, can cause serious side effects, and does nothing about the sickling itself. “We were hoping not to have to” put Camille on the drug, said her mother, Pamela Lonzer.A bone marrow transplant can cure the disease, but most patients can’t find a match, the procedure has a fatality rate of up to 5 percent, and patients need to be on anti-rejection drugs forever.While other discoveries of disease-causing mutations led to treatments and even cures in, for example, 26 years for cystic fibrosis or 16 years for HER2-positive breast cancer, the discovery of the sickle cell mutation has led to exactly zero after 60 years.Not that there haven’t been opportunities.Missed chancesPhysicians have long been struck by how some people with the sickle cell mutation are mostly fine, with few or none of the disabling symptoms. In 1948 scientists guessed why: These patients, hematologists wrote in a paper on “the paucity of sickle cells in newborn Negro infants,” were still making a form of hemoglobin that the body ordinarily stops producing in the first year of life. If just 15 percent or so of the body’s hemoglobin is “fetal hemoglobin,” scientists learned later, it keeps the disease at bay.Orkin, who had done pioneering research on thalassemia and other blood disorders as well as the genetics of normal blood cell development, was part of the team that in 1984 discovered that hydroxyurea somehow affects DNA so as to resume the production of fetal hemoglobin at levels more typical of infancy. He began searching for the genetic magic that accomplished that.He and his colleagues got clues by studying Saudi Arabian patients who had the sickle cell mutation but only mild symptoms thanks to the fetal hemoglobin they kept making into adulthood. But the genetic basis of that is “complex and requires interaction with additional factors,” Orkin and his colleagues wrote in 1989.It wasn’t a surrender, or a warning that the genetics of sickle cell were too tough to decipher. It was what, in many other fields, would be taken as a challenge, drawing hordes of young scientists to an intriguing puzzle.That did not happen. By the late 1980s, scientists knew that genetic on-off switches — transcription factors — were important for the development of blood cells. “But no one had a clue which transcription factors regulated the switch from fetal to adult hemoglobin,” said Orkin, who is also chairman of pediatric oncology at Dana-Farber. By sheer bad luck, his and other labs that set out to identify those molecules looked in the wrong kinds of cells, cells that didn’t make the switch. With barely a dozen labs working on sickle cell, the field didn’t have the critical mass that might have led someone to figure out what kinds of cells to use in experiments seeking the fetal-to-adult switch.They hit dead end after dead end, and with little incentive to keep hunting, “we went off and did other things,” said Orkin. “I like to do things that work, and sickle cell wasn’t working.” Sharon Begley [email protected] Leave this field empty if you’re human: Pamela Lonzer seconds that. When Camille was born with sickle cell disease, “I thought my world was ending,” she said. Although Camille, whose favorite school subjects are science and writing, has participated in research on exercise and pain, the family is still waiting for a clinical trial of a drug or other therapy that might actually cure her.“This is a disease that doesn’t get the attention or the funding it should,” Lonzer said. “There’s a stigma that comes from thinking it affects only African-Americans. People dismiss it by saying, ‘Oh, sickle cell patients just have pain.’”Efforts to cure sickle cell (as well as to alleviate some of its symptoms without going all the way to a cure) are underway at pharmaceutical companies and biotechs. Novartis announced last year that it is collaborating with Intellia Therapeutics, which hopes to develop treatments by using CRISPR genome-editing technology to switch the gene for fetal hemoglobin back on.That would probably be done by extracting progenitor blood cells from a patient, using CRISPR to increase production of fetal hemoglobin relative to adult hemoglobin, and then infusing fetal-hemoglobin-making cells back into the body. By targeting those progenitor cells, said Craig Mickanin of the Novartis Institutes for BioMedical Research, “you can repopulate the whole lineage.” But because only some cells have to make fetal hemoglobin, “we don’t feel we have to correct 100 percent of the cells.”Sangamo BioSciences is using a different genome-editing technique, called zinc fingers, to treat blood stem cells outside the body. But instead of disrupting BCL11A directly, Sangamo aims to disable an earlier step in the BCL11A process that Orkin and his team discovered in 2013. Called an enhancer, it is less likely to affect immune cells where BCL11A also operates, averting the risk of dangerous side effects.“Breaking the enhancer is more feasible than fixing the hemoglobin mutation,” said hematologist Dr. Daniel Bauer of Dana-Farber/Boston Children’s and a codiscoverer of the BCL11A enhancer. “I think we have a unique opportunity to cure sickle cell disease.”The American Society of Hematology plans to call for a sickle cell moonshot this fall. Thanks to the discoveries about the genetics of hemoglobin and the development of genome-editing technology, “we really do have opportunities” to develop a cure, said ASH vice president Dr. Alexis Thompson of Children’s Hospital of Chicago. “But we have to go after it with passion and urgency. The time is now.”ASH can do little more than make that plea to the public, elected officials, and the NIH, whose National Heart, Lung, and Blood Institute funds sickle cell research. But the institute also funds research on heart disease, which has a much larger constituency. “I am not holding my breath,” Orkin said.Williams is slowly getting governmental and other approvals for the small clinical trial he’s planning. He thinks a moonshot — with all the coordination, resources, and publicity that could bring — might organize multiple medical centers to participate in both this trial and, if it succeeds, larger ones. He hopes to start recruiting patients (two children, two teenagers, and two adults) in September.“This is absolutely going to work,” Williams said — if only someone would pony up $5 million. There are many theories about why that is, and why the lack of urgency and even interest extends to scientists. Fewer than a dozen US labs are working all-out on sickle cell disease, a number that has stayed constant for years, said Dr. Stuart Orkin of Boston Children’s. “I’m not sure why there are so few,” he said. “Maybe [the biology of sickle cell disease] seemed too simple, or maybe it isn’t sexy enough.”Or maybe the disease strikes the “wrong” people.advertisement Dr. Willis and Pamela Lonzer, with their daughter Camille, who has sickle cell disease, at their home in Chicago. Anne Ryan for STAT Please enter a valid email address. Related: He turned away from sickle cell research for about a decade, spending the 1990s on the genetics of normal blood cell development. He still thought about sickle cell disease, trying to imagine how the genetics of the fetal-to-adult hemoglobin switch worked. But no one was banging on his door to fund sickle cell experiments, no Hollywood charity dangled millions of dollars in grants in front of him.In the early 2000s, Harvard medical student Vijay Sankaran, working in Orkin’s lab, said he wanted to study the fetal-to-adult hemoglobin switch. Orkin asked if Sankaran was sure; he worried that Sankaran’s budding career would tank as a result of searching fruitlessly for the molecular genetics of sickle cell. His caution seemed to be borne out when, for nearly three years, Sankaran’s experiments repeatedly failed. It turned out he was looking for the crucial transcription factor gene on the wrong chromosome.An innovators’ maxim is to “fail fast,” so developers can quickly pivot from unproductive paths. If many scientists had been competing with Sankaran to find the gene, who knows if he would have abandoned his search on the X chromosome in weeks, not years. And who knows how much faster key discoveries would have been made.Sankaran finally bagged his quarry in 2008, when he — with others in Orkin’s lab — identified the gene that turns on production of adult hemoglobin. Called BCL11A, it’s located on chromosome 2. When they suppressed BCL11A in human cells growing in lab dishes and in mice, they reported in Science in 2011, blood cells kept making fetal hemoglobin and the mice were cured of sickle cell. Around that time, Sankaran and his team discovered another gene that helps flip the switch, called MYB; suppressing it, too, increased production of fetal hemoglobin.That opened the door to using gene therapy to cure sickle cell. Why fetal hemoglobin combats sickle cellVolume 90%Press shift question mark to access a list of keyboard shortcutsKeyboard ShortcutsEnabledDisabledPlay/PauseSPACEIncrease Volume↑Decrease Volume↓Seek Forward→Seek Backward←Captions On/OffcFullscreen/Exit FullscreenfMute/UnmutemSeek %0-9 facebook twitter Email Linkhttps://www.statnews.com/2016/05/19/sickle-cell-disease-cure/?jwsource=clCopied EmbedCopiedLive00:0001:0301:03  Our bodies switch from fetal blood to adult blood as we age. Here’s how the blood we have at birth could help those with sickle cell disease. Hyacinth Empinado/STAT ‘We didn’t scream enough’When David Williams was a newly minted physician 30 years ago, the Children’s Hospital hematology caseload was about evenly split between kids with hemophilia and kids in sickle cell crisis. Since then, treatments for hemophilia have become so successful that they’re practically cures, and children almost never show up with uncontrollable bleeding.“So we see almost all sickle cell,” Williams said, explaining why he jumped at the chance to build on Orkin’s discoveries. “It’s really sad that’s the case.”He began developing an experimental therapy based on the genetics of sickle cell, in particular the idea that knocking out only enough BCL11A to reactivate some fetal hemoglobin production should avert the devastating symptoms of the disease. Therapies that prevent BCL11A from flipping fetal hemoglobin to adult hemoglobin can therefore be far from perfect.But Williams immediately hit the same speed bump that Orkin and Sankaran had: too few resources. He needed a way to slip genetic material into cells, using a harmless virus (viruses are great at infiltrating cells). It took his lab two long years to figure out how to do that safely, partly because “I had only one postdoc working on it,” he said. “With more people, it would have taken much less time.” “Sickle cell patients have never been at the front of the line,” said Dr. David Nathan, 87, a past president of Dana-Farber who helped discover the only drug that partly treats it. “It strikes Italians, Greeks, blacks. … This work, especially clinical trials, is hugely expensive, and the National Institutes of Health and private foundations haven’t prioritized it.”Virtually every scientist thinks the disease he or she studies is underfunded. What’s different about sickle cell is that scientists can point to specific turning points when a few more people at the lab bench would have made a significant difference to the pace of progress, and to specific studies now on the drawing board that could, with a concerted national effort, cure the disease.“This is the right time for a sickle cell moonshot, a concerted effort to focus resources — not just financial resources but intellectual resources — on a goal,” said Williams. “The technology has advanced to the point where we can talk about curing this disease.” How sickle cell disease happensVolume 90%Press shift question mark to access a list of keyboard shortcutsKeyboard ShortcutsEnabledDisabledPlay/PauseSPACEIncrease Volume↑Decrease Volume↓Seek Forward→Seek Backward←Captions On/OffcFullscreen/Exit FullscreenfMute/UnmutemSeek %0-9 facebook twitter Email Linkhttps://www.statnews.com/2016/05/19/sickle-cell-disease-cure/?jwsource=clCopied EmbedCopiedLive00:0001:0601:06  In healthy people, blood cells are round and flexible. But in people with sickle cell disease, blood cells are deformed and cause a range of health problems. Hyacinth Empinado/STAT ‘I try not to think about it’Every year about 300,000 babies around the world are born with sickle cell disease, the result of a mutation in the gene for hemoglobin, the oxygen-carrying molecule in red blood cells. Only infants who inherit the defective gene from both parents — an estimated 100,000 people in the United States — have it.The mutation, discovered in 1956, causes red blood cells to cramp up into a crescent shape that makes them clump, impeding their flow through blood vessels. As a result, patients can suffer anemia, infections, fatal organ failure, tissue damage, strokes, and pain so intense it feels like a pickaxe-in-the-skull migraine everywhere in the body.Camille Lonzer had her first such sickle cell crisis, as the severe pain is called, a year ago, when she was 13, the latest blow from a disease that for years had sent her to the hospital with fevers and infections seemingly as often as other little girls go to birthday parties.Her parents, who work for pharmaceutical companies near Chicago, have been tireless in managing Camille’s sickle cell disease, including massaging her in an effort to keep her blood flowing and the pain at bay. So far, the disease has not kept Camille “from doing everything I want,” she said. But the arrival of the pain crises, she and her parents worry, might change that.“I try not to think about it,” she said. “I try to imagine myself somewhere else.” Senior Writer, Science and Discovery (1956-2021) Sharon covered science and discovery. Dr. David Williams very much hopes the White House’s $755 million “cancer moonshot” finds cures, that Sean Parker’s $250 million “Dream Team” brings effective immune-system treatments to every kind of tumor, and that the $370 million raised by Hollywood-based Stand Up to Cancer fuels discoveries that make malignancies as treatable as headaches.All Williams wants is $5 million — a rounding error to the billionaires making nine-figure donations to cancer research — to run a clinical trial that has a good chance of curing sickle cell disease.There is no moonshot for sickle cell. There are no “ice bucket challenges.” When fundraisers at Boston Children’s Hospital and Dana-Farber Cancer Institute, where Williams is president of the Cancer and Blood Disorders Center, ask donors to support sickle cell research, benefactors say they prefer to fund efforts that promise to help the adorable little kids stricken with cancer.advertisementcenter_img Related: In the LabWe’ve known for 50 years what causes sickle cell disease. Where’s the cure? Related: By Sharon Begley May 19, 2016 Reprints Global push gives hemophilia patients in developing world access to vital drug Privacy Policy His plan is to pack molecules called antisense RNAs into lentiviruses, which are as efficient at delivering genetic material into cells as pizzerias are at delivering menus into apartment-house vestibules. The viruses would carry the RNA into blood stem cells isolated from a patient’s bone marrow. Antisense RNA basically hogties the messenger molecules that carry instructions from the BCL11A gene, triggering a sequence of events that cause some blood cells to make fetal hemoglobin. That should keep at least some fetal hemoglobin from being switched to the adult form.“Most people think you’d have to correct only 10 to 20 percent of cells to cure somebody,” Orkin said. About 30 percent was enough to cure the mice in his 2011 Science study.Gene therapy would likely be too expensive for use in India and the African countries where sickle cell is common, so Orkin hopes a drug could tie up BCL11A. “That’s where I think a moonshot really is needed,” he said: drawing clever, imaginative researchers to find molecules able to disable enough BCL11A to keep enough cells making fetal hemoglobin to cure the disease.No one minimizes the long, hard slog that would take. The gap between biological discovery and disease treatment is so wide, it’s called the valley of death. Gene-activating molecules like BCL11A are often considered “undruggable,” meaning it’s very difficult to invent a compound that affects them. “But a moonshot would bring in structural biologists and chemists [and others] who could find a drug targeting BCL11A,” Orkin said.“You need people to think about, can you get molecules to bind to [BCL11A]?” Orkin said. “Can you get molecules that degrade it? … Those are not easy tasks.”The what-ifs — if 50, not 10, labs pursued sickle cell; if Orkin had been able to enlist more scientists in the 1990s transcription-factor hunt; if Williams had had the resources to support four or five postdocs looking for a safe vector — are impossible to answer. But “as a scientist and a physician, it’s one of my major frustrations,” said Williams, referring to how little support and attention sickle cell gets from scientists, funders, and the government. “This is a disease that devastates the families and the lives of the children.”“Maybe it’s our fault,” said Nathan about the paucity of resources devoted to sickle cell over the decades. “Maybe we didn’t scream enough” for more funding, more bodies, more attention. “But it’s just not right” how little attention the disease gets. Please enter a valid email address. Newsletters Sign up for Daily Recap A roundup of STAT’s top stories of the day. 5 strange disease outbreaks that still puzzle scientists About the Author Reprints @sxbegle Tags fundingsickle cell diseaselast_img read more

When might experimental drugs to treat Covid-19 be ready? A forecast

first_img Related: @matthewherper HealthWhen might experimental drugs to treat Covid-19 be ready? A forecast Convalescent plasmaTimeline: May see some use immediately, but research could take monthsIt’s an old idea that has proven effective in other epidemics: give patients who are sick blood plasma from those who have recovered. It can work because the plasma contains antibodies against the virus, weaponizing the immune system of the sick patient.One recent study from China reported that of 10 patients given convalescent plasma, seven saw their viral loads become undetectable; it noted other improvements in their condition.Takeda is developing a more refined version of this approach that uses more concentrated antibodies taken from blood. Julie Kim, the president of the company’s blood products division, said last Wednesday on a conference call with reporters organized by PhRMA, the trade group, that the product may be available in nine to 18 months.Arthritis drugsTimeline: Data could be available by summer; drugs available nowDrugs against autoimmune diseases like rheumatoid arthritis work by tamping down the immune system. This could, ironically, be useful against in Covid-19, because the SARS-CoV-2 virus can make the body overreact, causing what’s called a “cytokine storm,” damaging the body.Actemra, one such drug made by Roche, is approved for treating the cytokine storm when it is caused by cancer treatments. An unpublished 21-patient study in China showed Actemra reduced fevers and need for supplemental oxygen. Two other firms, Regeneron and Sanofi, launched a study of their similar drug, Kevzara, in Covid-19 patients; the pair has said results on fevers and oxygen use could be available as early as April. Roche has begun its own study of Actemra in the U.S. Both Actemra and Kevzara are artificial antibodies that target a protein involved in the immune system called IL-6, and are given by injection. Related: About the Author Reprints By Matthew Herper March 24, 2020 Reprints Tags Coronavirus There is a desperate need for new medicines to treat Covid-19, the disease caused by the novel coronavirus that has shut down much of the world. A vaccine to prevent infection entirely would be even better.Drug companies and medical researchers are making heroic efforts to deliver new medicines. Several dozen are now in development, and you can see highlights of those efforts here. Studies so far are mostly small and lack real control groups, making it hard for researchers to be sure of their conclusions. Doctors on the front lines have been trying older medicines, such as the malaria drugs hydroxychloroquine and chloroquine, in the hopes that they will prove effective. Large studies of such medicines are already in process.advertisement Matthew Herpercenter_img Existing antiviral medicinesTimeline: Available now, but efficacy testing could take a month or more.An existing, easy-to-produce medicine that proved effective at treating or preventing SARS-CoV-2 infection would provide the fastest relief for patients and doctors. The early hope is on hydroxychloroquine and chloroquine, and many hospitals, including the University of California, San Francisco, and the University of Washington, include them in their treatment guidelines. Some doctors are combining hydroxychloroquine with azithromycin, an antibiotic. Much of the published evidence comes from a very small French study and reports from China. Larger, more rigorous clinical trials are starting, but they will take time. Favipiravir, a flu drug shown in Japan, appeared beneficial in another small study. These medicines, especially the malaria drugs, which are being mass-produced, will be used by doctors on the front lines, but we will have to wait for evidence of whether they are benefitting patients and how much.RemdesivirTimeline: First data could come in AprilRemdesivir, an antiviral medicine that failed as an Ebola treatment, was initially developed to work against a different coronavirus. There’s some evidence that it benefits Covid-19 patients. Its maker, Gilead, has been working with researchers and governments around the world to get clinical trials up and running. The company has said to expect results in April. Six large studies are in progress, with the first, in severely ill patients in China, due to finish as early as April 3, according to a government website. A study in patients with milder disease will also finish in April, with two more due in May. In the meantime, Gilead has made the drug available to hundreds of patients on a compassionate use basis. However, it recently said that, due to overwhelming demand, it would suspend access to the drug for all but pregnant women and children as it works to create a more systematic way of giving it out without interfering with clinical trials. This new system should be in place soon. Remdesivir must be given intravenously. Artificial antibodies against the virusTimeline: Potentially early fallMany of the pharmaceutical industry’s best-sellers are what are called monoclonal antibodies, which are antibodies developed in mice and then made into drugs that can be injected into patients.A manufactured antibody, or a mix of manufactured antibodies, might have a more consistent impact than using blood plasma, and it can be off-the-shelf. Regeneron, the Tarrytown, N.Y., biotech, had success developing a mixture of antibodies against Ebola; it is now selecting two to use against SARS-CoV-2, with the expectation that trials could start by early summer. If all goes well, it could be available by early fall for some uses, like treating extremely sick patients. Eli Lilly, working with a Vancouver startup called AbCellera, has said it hopes to start trials of a similar approach within four months. Vir Biotechnology and Biogen are following a similar path. Antibodies might also be used to prevent infection, but that could take longer to test in studies.New antiviralsTimeline: 2021 at the earliestIf existing antivirals cannot control SARS-CoV-2, brand new medicines may be needed. But this process is at square one, and even moving at full-speed could eat up months. Efforts are underway to search chemical libraries for medicines that could prove effective by the Bill and Melinda Gates Foundation and others. If they can find medicines that have gone through some previous testing, as remdesivir has, that could hasten the process.VaccinesTimeline: Late 2021, possibly many yearsThere is one approach that could deliver a vaccine faster than others: It uses messenger RNA to make cells produce proteins that could lead to immunity. This approach has never been used in a widely available vaccine. The biotech Moderna is in the lead here, but others, such as BioNTech, working with Pfizer, are working on a similar approach.It could take 18 months to be sure that approach works and is broadly safe. Even with increased manufacturing capacity, supply could be a problem. Other approaches are being developed in tandem, including one from Sanofi, now used for flu vaccines, that manufactures vaccines in insect cells. However, Moderna said in a filing with the SEC Monday that its vaccine might be available for some groups, including health care workers, as early as fall 2020.“If you look across the many programs that have been launched, if you look at history, not all of those programs will be successful,” said Rajeev Venkayya, president of Takeda’s global vaccines unit, during a press conference last week. “And I think that is something that I don’t think we’ve effectively communicated to the public. Just because we start a vaccine program doesn’t mean that we will definitely get a vaccine on the other end.”The good news about having so many efforts in progress, he said, is it increases the chances that one will succeed. [email protected] As Covid-19 spreads, disruptions to clinical trial and drug development accelerate Senior Writer, Medicine, Editorial Director of Events Matthew covers medical innovation — both its promise and its perils. People who believe they have Covid-19 and who meet the criteria wait in line to be pre-screened for the coronavirus outside of the Brooklyn Hospital Center. ANGELA WEISS/AFP via Getty Images STAT Reports: STAT’s guide to interpreting clinical trial resultsBut the relentless pace of the virus’ spread and a sense of desperation can only do so much to speed up the development of new medicines. Normally, the process to develop new medicines can take a decade or more. And many experimental medicines fail. When it comes to infectious disease treatments, data from the Biotechnology Innovation Organization put the success rate of new medicines just starting clinical testing at 1 in 5.  Is there hope that something will be available soon to help us fight this virus, known as SARS-CoV-2? Here’s a look at what’s on tap and how soon it could be ready. For almost any treatment or preventative, supply could be an issue if large numbers of people need it. Lastly, please note: Some of these timelines could shift, and some of these treatments and vaccines are likely to fail. That is the unfortunate reality of how medicine works. advertisement An updated guide to the coronavirus drugs and vaccines in development last_img read more

Delighted Desmond and courageous Clodagh revel in Laois Camogie win

first_img Laois Councillor ‘amazed’ at Electric Picnic decision to apply for later date for 2021 festival Delighted Desmond and courageous Clodagh revel in Laois Camogie win TAGSClodagh TynanJohn DesmondLaois Camogie Pinterest WhatsApp John Desmond and Clodagh Tynan Laois camogie manager John Desmond and wing back Clodagh Tynan were in jubilant form as their team reached the All-Ireland Camogie championship semi final yesterday.Things looked very bleak for Laois with less than 15 minutes to ply as they had only managed to score once in the opening three quarters of the game and were down by five points.However, they refused to give up and dragged themselves back into the game before forcing extra time and eventually winning.Speaking to Killian Whelan on the Camogie Association Facebook page afterwards, manager Desmond paid particular tribute to the half back line too.He said: “The players dug in deep because that game was gone from us – absolutely gone.“But we made a few changes and we had a few players playing their first ever games of inter-county and the stepped up to the mark.“The performance was outstanding. Our half back line started working and we can be a bit lazy there sometimes but when they got going they were impassable.“The weather was so tough, the pitch was soft and the ball was sticking in the muck which didn’t suit us.“But we got the result thank god.”Wing back Clodagh Tynan fired the last two points of normal time which forced extra time.The St Brigid’s defender’s second score was virtually the final puck of normal time and it was from considerable distance.But she was very modest about it and can’t wait for Saturday’s semi final against Antrim.She said: “I would’ve probably written us off too to be honest (after 45 minutes) but we fight just to have the outlet (of playing sport) because we are so lucky to be able to play.“The older girls really stood up and they have such experience. We drove on then and as a unit we got over the line.“I was lucky just to be in the right place at the right time – any of the girls are capable of popping them over.“We’ve lucky to have the management team and they are putting in a lot of time with us.“It isn’t easy in the circumstances but we are just delighted to get the win now and we will drive on for the next day.”Laois will now face Antrim next Saturday for a place in the All-Ireland final.SEE ALSO – Laois priest scoops top prize in Carlow GAA draw Electric Picnic WhatsApp RELATED ARTICLESMORE FROM AUTHOR Facebook Home GAA Camogie Delighted Desmond and courageous Clodagh revel in Laois Camogie win GAACamogieSport Twitter Electric Picnic Pinterest Previous articleLaois rugby club unveil drive to get more girls involvedNext article‘Physicality is one thing but it’s also the accuracy and skills with which they play the game’ Alan HartnettStradbally native Alan Hartnett is a graduate of Knockbeg College who has worked in the local and national media since 2008. Alan has a BA in Economics, Politics and Law and an MA in Journalism from DCU. His happiest moment was when Jody Dillon scored THAT goal in the Laois senior football final in 2016. News Bizarre situation as Ben Brennan breaks up Fianna Fáil-Fine Gael arrangement to take Graiguecullen-Portarlington vice-chair role By Alan Hartnett – 16th November 2020 Facebook Twitter Electric Picnic organisers release statement following confirmation of new festival datelast_img read more

Court rejects former banker’s lawsuit against TD subsidiaries

first_img The retirement plan fell apart when the markets did not perform as expected, the court notes: “The investment retirement plan for these funds he was expecting to achieve unfortunately was not realized, and, in fact, the plaintiff unfortunately found himself in a position where a substantial portion of the funds were going to be exhausted long before anticipated.” Webb sued the firms, claiming he was given bad advice to take the commuted value of his pension rather than staying in the plan. The firms argued that the case was brought after the two-year limitation period and that there’s no genuine issue for trial. The court sided with the firms, ruling that Webb would have known about the possible grounds for a claim by 2009 or 2010 at the latest, but that he didn’t bring his claim until 2014. “There was a lack of diligence on [Webb’s] part and he took no steps to investigate his concerns when he could have,” the court said in dismissing the case. The court also noted that Webb veered off the investment plan in the aftermath of the financial crisis when he, “panicked and jumped in and out of investments.” Photo copyright: aruba2000/123RF James Langton Court approves data breach settlements with BMO, CIBC Bitcoin surge doesn’t affect damages, B.C. court says Universal life policies can’t be used for unlimited deposits, appeal court rules MFDA bans former rep for recommending unsuitable strategy The Ontario Superior Court of Justice has dismissed a lawsuit from former banker Robert Webb against TD Waterhouse Canada Inc. and TD Waterhouse Financial Planning, who alleged he received poor advice from the firms, his former employers, when he elected to take the commuted value of his pension and invest it rather than staying in the parent bank’s pension plan after he was terminated in 2005. Keywords Lawsuits Facebook LinkedIn Twitter Share this article and your comments with peers on social media Related newslast_img read more

Tourism: A key sector in planning Outaouais’ economic recovery

first_imgTourism: A key sector in planning Outaouais’ economic recovery From: Canada Economic Development for Quebec RegionsCanada Economic Development for Quebec Regions grants $1M to help Nordik Spa-Nature to maintain its activities and pursue its growth.Chelsea, Quebec, January 18, 2021 – Canada Economic Development for Quebec Regions (CED)Around the world, tourism was one of the first industries affected by the pandemic; it will also be one of the last to be able to return to full working order. A pillar of the Canadian economy that generates $102 billion a year and represents 4% of all jobs (or the equivalent of 1.8 million workers), tourism is a major vector to diversify and develop the economy.Entrepreneurs in this sector- composed mostly of SMEs-have demonstrated resiliency, creativity and adaptability since the crisis began. To support them, the Government of Canada, through Canada Economic Development for Quebec Regions (CED), is signalling its presence with a contribution of $1 million to boost tourism in the Outaouais region.Helping tourism organizations make it through the crisisSince the start of the crisis, the Government of Canada has been supporting organizations in the tourism industry, including through the Regional Relief and Recovery Fund (RRRF), deployed in Quebec by CED and its collaborators. As a reminder, the RRRF has made it possible to provide funding and technical support to businesses and organizations to help them maintain their activities. In this way, with the help of Sociétés d’aide au développement des collectivités (SADCs), Centres d’aide aux entreprises (CAEs) and PME MTL, 1167 organizations in Quebec’s tourism sector have received contributions through the RRRF totalling over $44 million. Thanks to this measure, some 9400 jobs have been maintained.The Member of Parliament for Pontiac and Parliamentary Secretary to the Minister of Innovation, Science and Industry (Science), William Amos, on behalf of the Honourable Mélanie Joly, Minister of Economic Development and Official Languages, today announced a repayable contribution of $1 million from the Government of Canada for Nordik Spa-Nature to enable it to rehire 121 employees in Chelsea on a short-term basis and strengthen its operations to pursue growth.The tourism industry, which plays a crucial role in the economic, social and cultural life of communities, represents an essential link in regional economic development. Through this support, the Government of Canada is attesting to its commitment to prepare the field for after the pandemic with a view to rebuilding a stronger, more resilient and more just economy for all.Quotes“The tourism industry has been hit hard by the pandemic, and the Government of Canada is committed to accompanying key players as they prepare to rebound vigorously after the economic crisis. We have been here since the start of this unprecedented situation, with concrete measures, and we will be here to support tourism as the health situation evolves. We must plan the economic recovery, which can only happen with the contribution of players in the tourism community, so that we can get off to a new start together and be stronger and more resilient.”The Honourable Mélanie Joly, Member of Parliament for Ahuntsic-Cartierville, Minister of Economic Development and Official Languages and Minister responsible for CED“The CED assistance announced today highlights our willingness to support the tourism industry and our commitment to Canadian businesses, organizations and citizens in these difficult times. The financial contribution granted to Nordik Spa-Nature is very good news for the Outaouais region and its attractiveness. Thanks to Government of Canada investments in the tourism industry, we are ensuring we will be ready to receive tourists from home, and then from around the world!”William Amos, Member of Parliament for Pontiac and Parliamentary Secretary to the Minister of Innovation, Science and Industry (Science)“I am delighted with this support announced today for an attraction that is a pillar for the Outaouais region. It is extremely valuable because it will also enable us to solidify an accommodation project in the RCM of Collines-de-l’Outaouais. Since the beginning of this crisis, the efforts our federal partners have made to listen to the tourism industry’s difficulties have been greatly appreciated.”France Bélisle, President and Chief Executive Officer, ATR de l’Outaouais“Before the pandemic, our business had many projects under development in Canada, including several we had to put on hold starting in March. The repayable contribution obtained through this program is welcome as it helps us cover expenses already committed to in ongoing projects to grow and improve operations. We are confident that the recovery will slowly take off in a few months, and we will once again be able to welcome our faithful visitors.”Martin Paquette, Founder and President, Groupe NordikQuick factsCED is a key federal partner in Quebec’s regional economic development. With its 12 business offices, CED is present to accompany Quebec businesses, supporting organizations and regions into tomorrow’s economy.The Honourable Mélanie Joly, Minister of Economic Development and Official Languages, is the minister responsible for the six regional development agencies (RDAs), including CED.Recognizing the importance of the Regional Relief and Recovery Fund (RRRF) in supporting local tourism businesses, the Government of Canada proposed as part of the Fall Economic Statement (November 2020) an additional $500 million for RDAs.Total funding for the RRRF sits at over $2 billion, and at least 25% of this amount will be granted to boost local tourism businesses, representing over $500 million in support to kickstart tourism by June 2021. /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:business, Canada, community, creativity, Economic Development, Employees, entrepreneurs, France, Government, industry, innovation, Minister, parliament, President, regional development, Secretarylast_img read more

Republicans Vicki Kraft, Karen Bowerman complete their comebacks

first_imgRepublicans Vicki Kraft, Karen Bowerman complete their comebacksPosted by ClarkCountyToday.comDate: Tuesday, November 10, 2020in: Newsshare 0 Kraft will return to Washington State Legislature and Bowerman will join the Clark County CouncilIt appears that Republicans Vicki Kraft and Karen Bowerman have completed their respective comebacks in the Nov. 3 general election. On Monday, the Clark County Elections Department released election results that accounted for all but what is expected to be a total of about 2,500 remaining votes. blankIn the race for state representative, position No. 1 in the 17th Legislative District, the incumbent Kraft had opened up a lead of 1,791 votes over Democrat challenger Tanisha Harris, who held an advantage of 1,162 votes after Tuesday’s initial report. Kraft has 51.10 percent of the votes and Harris has 48.9 percent. Two years ago, Kraft defeated Harris by just 859 votes. “I want to thank the people of the 17th Legislative District for the opportunity to continue serving them as their State Representative in Olympia,’’ Kraft wrote in an email to Clark County Today Tuesday. “I’m very thankful for all the prayers and support I’ve received, it’s made all the difference in winning this race.’’In the race for the Clark County Council District 3 position, Democrat Jesse James had an advantage of 1,110 votes over Bowerman Tuesday night. After Monday’s report, Bowerman had moved ahead by 1,649 votes. Bowerman has 51.47 percent and James is at 48.53 percent. blank“With only 2500 votes remaining to be counted county-wide, and a comfortable margin, I now simply want to say ‘thank you’ to voters of District 3 for your confidence in my representing you,’’ Bowerman wrote in an email to Clark County Today Tuesday. Heading into today’s report, the elections department had counted 273,554 ballots, or 84.52 percent of the county’s 325,144 registered voters. The turnout didn’t reach the estimate of as many as 90 percent registered voters, but it obviously followed the national trend for this presidential election cycle. Monday’s report included just 1,265 new ballots counted. In Clark County, the election will be certified on Nov. 24.AdvertisementThis is placeholder textTags:Clark CountyElection 2020LatestVancouvershare 0 Previous : CMAC to post video featuring area veterans Next : VIDEO: Local World War II veterans share their experiences – Part One: Stanley ColemanAdvertisementThis is placeholder textlast_img read more